We specifically focussed on mutations in the PI3K pathway and readouts of pathway activity, as well as activation status of K‐Ras, as K‐Ras mutations are predictive of resistance to everolimus in colorectal cancer (Di Nicolantonio et al., 2010). Here, KRAS is linked to colorectal cancer.